September 21st 2021, 9:00pm
Polymerase chain reaction–based comprehensive genomic profiling testing provided useful information for more than 94% of samples, including 81% of samples that normally would not have been tested, suggesting that more patients may benefit from CGP testing than anticipated.
September 18th 2021, 4:20pm
Investigators confirmed prognostic biomarkers for premenopausal patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, which could potentially be used to inform treatment decisions.
September 15th 2021, 9:20pm
A literature review detailed the multitude of ways that liquid biopsy can be used to aid the treatment of patients with cancer, including aiding in screening, recurrence surveillance, genomic profiling, and therapeutic decision-making.
September 11th 2021, 5:00pm
Investigators identified 5 mutated genes that could serve as biomarkers for disease prognosis and clinical outcomes associated with pancreatic ductal adenocarcinoma, a common cancer with a high mortality rate and poor prognosis.
September 3rd 2021, 8:01pm
Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.
September 2nd 2021, 2:00pm
Using whole genome sequencing, copy number signatures were successful in predicting both the presence of chromothripsis and clinical outcomes in patients with newly diagnosed multiple myeloma (MM).
August 26th 2021, 8:22pm
Foundation Medicine and Epic struck a deal to integrate comprehensive genomic profiling within Epic's electronic health records (EHRs), allowing for providers to order and review genomic profiling tests, leading to more streamlined clinical decision making.
August 25th 2021, 7:30pm
Approximately 1 in 6 healthy individuals who underwent proactive genetic screening had genetic variants linked to increased risk for developing medically actionable disorders, including certain cancers and cardiovascular disorders.
August 18th 2021, 8:15pm
Investigators examined the current bodies of evidence surrounding the emergence of next-generation gene sequencing, and the challenges that come with it, for identifying oncogenic drivers of early-stage non–small cell lung cancer (NSCLC).
August 11th 2021, 4:00pm
This study shows little evidence of harms or increased health care utilization for people receiving negative (normal) results of expanded carrier screening through genome sequencing.
